
Midatech Pharma (NASDAQ: MTP) has the full commercial launch of Zuplenz (ondansetron) in the US. The drug is an oral …
A novel formulation of ondansetron has seen its marketing application delayed at the US Food and Drug Administration (FDA) because …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

